HCW Biologics Inc.

HCW Biologics Inc. announced the pricing of a $1.6 million private placement offering. The company issued 618,682 units, each comprising common stock or a pre-funded warrant, and the right to receive a common stock purchase warrant, to accredited investors including key management. The net proceeds are intended for working capital, general corporate purposes, and continuing clinical development activities. The issuance of the common warrants is contingent upon stockholder approval.

HCW Biologics Inc. announced the pricing of a $1.6 million private placement offering with a group of investors, including company officers and directors. The offering involves 618,682 units, each comprising common stock (or pre-funded warrants) and the right to receive common stock purchase warrants, pending stockholder approval. The net proceeds will fund clinical trials for HCW9302, advance IND-enabling studies for HCW11-018b and HCW11-040, and support general corporate purposes.

HCW Biologics Inc. announced the settlement and extinguishment of $2.8 million in disputed accounts payable during the three months ending June 30, 2026. This includes the resolution of a lawsuit and a $1.1 million mechanics' lien with B&I Contractors, Inc. Additionally, the company fully settled its obligations with EirGenix, Inc., reducing manufacturing costs from $1.7 million to $1.2 million through a settlement agreement.

HCW Biologics Inc. announced that it has regained compliance with Nasdaq's Bid Price Rule, Listing Rule 5550(a)(2), as determined by the Nasdaq Hearings Panel on June 29, 2026. The company will be under a mandatory monitoring period until June 17, 2027. To maintain long-term compliance, HCW Biologics will implement a one-for-six reverse stock split on June 30, 2026.

HCW Biologics Inc. announced a 1-for-6 reverse stock split, effective June 30, 2026, to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. The Board of Directors approved the split after stockholders granted the authority, aiming to prevent automatic delisting. The reverse split will reduce the number of outstanding shares and adjust options and warrants proportionately, with fractional shares rounded up.

HCW Biologics Inc. announced its Board of Directors approved a 1-for-6 reverse stock split of its common stock, effective June 30, 2026. The split is intended to ensure ongoing compliance with the Nasdaq Bid Price Rule and other requirements from a Nasdaq Hearings Panel, which had mandated the stock trade above $1.00 for 20 days prior to July 29, 2026. The company's common stock completed 28 consecutive trading days above $1.00 as of June 25, 2026, but the split is still deemed necessary to maintain compliance. The number of outstanding shares will decrease from 9,581,079 to approximately 1,596,849.

HCW Biologics Inc. filed an S-1 registration statement amendment on June 18, 2026. The filing primarily serves to update the exhibit index, incorporating various agreements and documents by reference or furnishing them. The remainder of the registration statement is unchanged.

HCW Biologics announced positive preliminary human data from the first two dose cohorts of its dose-escalating Phase 1 clinical trial for HCW9302, an IL-2 based fusion immunotherapeutic, in patients with alopecia areata. All three participants in the second dose cohort (3 micrograms/kg) showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores, with a >=25% reduction compared to baseline. The treatment was well tolerated, with no dose-limiting toxicities or significant IL-2-treatment-related adverse effects, including no reported incidence of capillary leak or cytokine release syndrome. The company aims to establish the Recommended Phase 2 Dose by year-end 2026 and plans to explore multi-dose studies for alopecia areata and other autoimmune diseases.

HCW Biologics announced positive preliminary human data from the first two dose cohorts of its Phase 1 clinical trial for HCW9302 in patients with alopecia areata. All three participants in the second dose cohort (3 micrograms/kg) showed preliminary indications of improvement with a ">=25%" reduction in SALT scores. The IL-2 based fusion immunotherapeutic was well tolerated, with no dose-limiting toxicities or significant adverse effects. The company projects to establish the Recommended Phase 2 Dose by year-end 2026 and plans to explore multi-dose studies and other autoimmune indications.

HCW Biologics Inc. has filed an S-1 registration statement for the resale of up to 5,693,950 shares of common stock by selling stockholders. This includes shares from a recent PIPE transaction and warrants. The company also received a Nasdaq exception to regain compliance with the minimum bid price rule by July 29, 2026, and elected to terminate a license agreement with Wugen Inc.